Additionally, high blood pressure can damage blood vessels throughout the body, leading to complications such as peripheral artery disease, vision loss, and cognitive decline. Furthermore, ...

Aerovate Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, focusing on developing therapies for pulmonary arterial hypertension. The company recently announced its ...

Serge Belanger’s rating is based on a clear path toward FDA approval and the subsequent launch of Yutrepia, a drug developed by Liquidia Technologies for treating pulmonary arterial hypertension (PAH) ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Authors of a recent review shared expert insights and tips for conducting cardiac catheterization procedures to diagnose ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...

Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

The following is a summary of “Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial,” ...

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the ...